Evidence map›Paper›PMID 41157135›Full record

ArticleMolecules (Basel, Switzerland)2025

Deciphering the Impact of Mutations on

Emilie Guémas, Sandie Ménard, Nicolas Jeanne, Georges Landa, Antoine Berry, Marie Brut

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emilie GuémasLaboratoire d'Analyse et d'Architecture des Systèmes (LAAS)-CNRS, Université de Toulouse, CNRS, 31031 Toulouse, France.ORCID 0000-0002-0168-7575
Sandie MénardInstitut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université de Toulouse, CNRS UMR 5051, INSERM UMR 1291, 31024 Toulouse, France.ORCID 0000-0001-6972-3598
Nicolas JeanneLaboratoire d'Analyse et d'Architecture des Systèmes (LAAS)-CNRS, Université de Toulouse, CNRS, 31031 Toulouse, France.ORCID 0000-0001-7109-3353
Georges LandaLaboratoire d'Analyse et d'Architecture des Systèmes (LAAS)-CNRS, Université de Toulouse, CNRS, 31031 Toulouse, France.ORCID 0000-0001-6639-4530
Antoine BerryInstitut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université de Toulouse, CNRS UMR 5051, INSERM UMR 1291, 31024 Toulouse, France.ORCID 0000-0002-6626-7766
Marie BrutLaboratoire d'Analyse et d'Architecture des Systèmes (LAAS)-CNRS, Université de Toulouse, CNRS, 31031 Toulouse, France.ORCID 0000-0002-2218-052X

Funding

Agence Nationale de la Recherche ANR-24-CE35-2805
6 · The paper itself

Abstract

The antimalarial combination of sulfadoxine-pyrimethamine is used as a preventive treatment in pregnant women and children in Africa. Sulfadoxine inhibits the

Indexed as

Dihydropteroate SynthaseMolecular Dynamics SimulationMutationPlasmodium falciparumSulfadoxineAntimalarialsCatalytic DomainHumansProtein BindingAntimalarialsDihydropteroate SynthaseSulfadoxinedhpsdrug resistancemolecular dynamic simulationsPlasmodium falciparumsulfadoxine

Identifiers

PMID41157135
PMCPMC12566285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.